(MedPage Today) -- The FDA approved tapinarof cream 1% (Vtama) for eczema in individuals ages 2 years and older, drugmaker Organon announced on Monday.
Approval of the topical aryl hydrocarbon receptor agonist was supported by the pivotal ADORING...

MedPage Today

New York

United States

Nonsteroidal Topical OK'd for Atopic Dermatitis

In a subset of patients in a 48-week extension trial, the mean duration of the first treatment-free interval was approximately 80 consecutive days.

Medscape

FDA Approves Topical Tapinarof for Atopic Dermatitis

Ad Fontes Media

Media Bias/Fact Check

The FDA has approved tapinarof cream, 1% for the treatment of atopic dermatitis in adults and pediatric patients over 2 years old. Marketed by Organon as VTAMA, tapinarof cream was initially approved in May 2022 for plaque psoriasis. Results from ADORING studies showed significant improvement in AD symptoms with tapinarof cream compared to vehicle alone. Common adverse reactions include respiratory infections, folliculitis, and headaches. In an …

Dataemia

The approval builds on previous indications for tapinarof, an aryl hydrocarbon receptor agonist, for the topical treatment of atopic dermatitis.

Pharmacy Times

FDA Approves Tapinarof Cream 1% for Treatment of Atopic Dermatitis in Adults, Children 2 Years and Older

Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label

Pharmaphorum

Galderma adds new indication for blockbuster hope Nemluvio

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis.

ajmc.com

FDA Approves Tapinarof Cream 1% for Patients With Atopic Dermatitis

This approval announcement by Galderma follows the previous FDA approval of nemolizumab for prurigo nodularis.

hcplive.com

FDA Approves Nemolizumab for Individuals with Atopic Dermatitis

The US FDA has approved Galderma's Nemluvio (nemolizumab), for individuals aged 12 years and above with moderate-to-severe atopic dermatitis.

pharmaceutical-technology.com

FDA approves Galderma's Nemluvio to treat atopic dermatitis

This latest approval is the second indication of the monoclonal antibody, Nemluvio. It was first approved in Aug. 2024 to treat patients with prurigo nodularis.

Managed Healthcare Executive

FDA Approves Nemluvio for Atopic Dermatitis

Nemolizumab is intended for use in combination with topical corticosteroids and/or calcineurin inhibitors in this indication.

Nonsteroidal Topical OK'd for Atopic Dermatitis

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics